Spots Global Cancer Trial Database for Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)
Official Title: Addition of Vandetanib to Standard Therapy (Pegliposomal Doxorubicin) in Patients With Recurrent Ovarian Cancer. A Multicentre Phase I / Randomized Phase II Study
Study ID: NCT00862836
Conditions
Interventions
Study Description
Brief Summary: This multi-centre, non-randomized open phase I/randomized phase II study will be conducted in 70 patients (10 in phase I, 60 in phase II) with platinum-refractory recurrent epithelial cancer of the ovary, fallopian tube or peritoneum. A total of approximately 5 national centers will participate in phase I of the study. If the starting criteria for phase II of the study are met at the end of phase I, a total of approximately 20 national centers will participate in phase II of the study.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Research Site, Ulm, Baden-Württemberg, Germany
Research Site, Wiesbaden, Hessen, Germany
Research Site, Essen, Nordrhein-Westfalen, Germany
Research Site, Kiel, Schleswig-Holstein, Germany
Research Site, Berlin, , Germany
Contact Details
Name: Clinical Sciences & Operations
Affiliation: Sanofi
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
